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Perilous Passivity:
The Insufficient Response to Antimicrobial Resistance
INTRODUCTION
Antimicrobial resistance is a growing problem with a global scope. If left unaddressed, it
threatens to diminish the effectiveness of antibiotic, antiviral, and antifungal medications. These
medications, in tandem with vaccination, are largely responsible for the dramatic decline in the
spread and mortality of infectious diseases worldwide since penicillin was first mass produced in
1941. Thus, they are major contributing factors to one of the great achievements of modern
humanity: the reduction of global childhood mortality in from between 30% and 50% in the 19th
century to less than 0.5% today in industrialized nations.1
Repeated use of antimicrobial products causes antimicrobial resistance to develop. As
antimicrobial-resistant traits emerge and spread to pathogens, they threaten the security from
infectious diseases that antimicrobial medicines grant to society. Therefore, to preserve the lifesaving power of these medicines, antimicrobial products must be used judiciously. However, in
practice, they are used wantonly and without regard to the gradual, building effects of their
overuse throughout the world. This is especially prevalent in commercial settings, as over 80%
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Child Mortality, OUR WORLD IN DATA, https://ourworldindata.org/child-mortality (last visited
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of antimicrobial products are used for agriculture.2 Nevertheless, it is similarly imperative to
control their medical uses, as up to 50% of antibiotic prescriptions in the United States alone are
either sub-optimal or entirely unnecessary.3
The tension between the long-term need to preserve the effectiveness of antimicrobial
products and the immediate benefits of their use lies at the heart of the crisis surrounding
resistance. To that end, the object of an effective regulatory scheme should be to deter the use of
antimicrobials solely for profit or convenience, and to confine them to settings where their use is
medically appropriate.
Alongside regulation, research and development of novel drugs with antimicrobial effects
that are not currently countered by resistance traits can be an effective tool in solving this crisis.
However, no drug is immune to the process by which resistance develops; even novel drugs will
in time become subject to the same limitations that current drugs face.4 Research and
development alone, without simultaneous regulation of the use of currently effective drugs,
cannot completely ameliorate the problem.
Thus, governments throughout the world have a responsibility to regulate the use of
antimicrobials in industry. Because the problem is of a global scale, there are global efforts to
coordinate a response. Correspondingly, the United States government has taken steps to combat
the problem within its own borders. Although totality of these efforts, both national and
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The Overuse of Antibiotics in Food Animals Threatens Public Health, CONSUMERS
UNION(2013), https://consumersunion.org/news/the-overuse-of-antibiotics-in-food-animalsthreatens-public-health-2/ (last visited Dec 14, 2018).
3 TOM FRIEDEN, ANTIBIOTIC RESISTANCE THREATS IN THE UNITED STATES, 2013(2013).
4 Julian Davies & Dorothy Davies, Origins and Evolution of Antibiotic Resistance,
3 MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS417–433 (2010),
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international, offer promising courses of action and demonstrate situational awareness, they are
nevertheless insufficient to impede the rampant progression of antimicrobial resistance. In many
areas, more stringent regulation is required to stop this threat to global public health. Without
disrupting the monetary incentives that exist to use antimicrobial products in situations that are
not medically necessary, the problem will not lessen.
SCOPE AND MECHANICS
In order to accurately assess the appropriateness of measures taken to combat
antimicrobial resistance, or suggest new ones, it is necessary to understand both the scope of the
problem, and certain key scientific concepts that would affect the efficaciousness of any
candidate policy.
A. Scope of the Problem
Antimicrobial resistance affects every nation on Earth, but it affects developing nations
especially grievously. In Europe, antimicrobial-resistant pathogens are responsible for over
25,000 fatalities and 2.0 million extra hospital days per year.5 In Thailand, they are responsible
for 25,000 fatalities and 3.2 million extra hospital days per year.6 This is substantially larger
relative to its population than the number of fatalities in Europe. Furthermore, that burden is felt
substantially by the child and infant population. In India, antimicrobial-resistant pathogens are
responsible for 58,000 infant deaths per year.7 This number exceeds the combined total fatalities
in the examples of Europe and Thailand. Even relative to India’s larger population, the number
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Antibiotic / Antimicrobial Resistance (AR / AMR), CENTERS FOR DISEASE CONTROL AND
PREVENTION(2018), https://www.cdc.gov/drugresistance/about.html (last visited Dec 14, 2018).
6 Id.
7 Id.
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of infants affected is disproportional. Furthermore, these numbers are growing as superfluous use
of antimicrobials continues.8
In the United States, antimicrobial-resistant pathogens are responsible for 23,000 fatalities
and over 2.0 million extra hospital days.9 This puts additional logistical and financial strain on an
already overburdened healthcare system that is dealing with a physician shortage, an uninsured
population of 28.9 million,10 and an underinsured population of 41 million.11 In addition to these
deaths and illnesses, the United States deals with 15,000 deaths and nearly 500,000 cases of
Clostridium difficile per year.12 Because people taking antibiotics are 7 to 10 times more likely to
contract C. difficile,13 this is yet another compounding effect of the overuse of antibiotics by
medical professionals. Similar to the worldwide trend, these numbers form an increasing trend of
complications that arise from antimicrobial resistance.14
B. Causes of and Contributors to the Problem
There are two main forces that contribute to the development of antimicrobial resistance:
medicine and agriculture. Each of these two causes carries its own set of challenges that must be
overcome to effectively combat the problem. Despite this distinction, however, the two share
common ground. Both have entrenched systems that monetarily incentivize the use of antibiotics
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10 National Center for Health Statistics, CENTERS FOR DISEASE CONTROL AND
PREVENTION(2017), https://www.cdc.gov/nchs/fastats/health-insurance.htm (last visited Dec 14,
2018).
11 Sara R. Collins, Munira Z. Gunja & Michelle M. Doty, HOW WELL DOES INSURANCE
COVERAGE PROTECT CONSUMERS FROM HEALTH CARE COSTSCOMMONWEALTH FUND,
https://www.commonwealthfund.org/sites/default/files/documents/___media_files_publications_
issue_brief_2017_oct_collins_underinsured_biennial_ib.pdf (last visited Dec 14, 2018).
12 CDC. Antibiotic Use in the United States, 2017: Progress and Opportunities. Atlanta, GA: US
Department of Health and Human Services, CDC; 2017.
13 Id.
14 Id.
9
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when not medically necessary. Both are in fact parts of a larger, interconnected network of
associations that spreads reserves of resistant traits throughout the microbial populations of the
country:
Figure 115:

Figure 1 demonstrates that superfluous use of antimicrobial products anywhere
contributes to the problem of antimicrobial resistance everywhere. It is impossible to solve this
crisis by focusing solely on one area where a reserve of antimicrobial resistance exists. Because
of the communicability of resistance traits between separate populations of microbes, stopping,
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Davies & Davies, supra note 4.
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for example, only the medical overuse of antibiotics without even considering the other reserves
of resistance would not impede the exacerbation of the problem overall.
C. Some Essential Scientific Concepts
It is difficult to understand the effects of policy regarding antimicrobial resistance without
understanding certain conceptual elements of the mechanics of its development and spread.
Chief among these concepts is selective pressure, a term in evolutionary biology that
refers to one of the driving forces of evolution by natural selection, or the idea that organisms
gradually change over time based on which organisms have traits that make them more likely to
survive and reproduce.16 When a factor causes some members of a population to be more likely
to survive and reproduce than other members of the same population, evolutionary biologists call
that factor a selective pressure.17 For example, limited access to water is a selective pressure that
shaped the evolution of flora and fauna in deserts around the world. Cacti exist in deserts in large
part because plants that are best at storing and economizing water are more likely to survive and
reproduce in deserts than plants that are not.
In the case of antimicrobial resistance, every time an antimicrobial product is used, it
applies an extremely heavy selective pressure to the population of microbes it comes into contact
with.18 It kills the vast majority of them, and the few survivors are far more likely to have traits
that resist the antimicrobial effects. These survivors repopulate, creating an entirely new
generation of bacteria, all of which share the increased resistance of the generation before it. 19 A
single application of selective pressure has a negligible effect, but the timeframe for a generation

16

Glossary, ALLIANCE FOR THE PRUDENT USE OF ANTIBIOTICS,
http://emerald.tufts.edu/med/apua/about_issue/glossary.shtml (last visited Dec 14, 2018).
17 Id.
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of bacteria can be a matter of minutes. The repeated application of this heavy selective pressure
causes the buildup of resistant traits over time and can render some populations of bacteria
resistant to many types of antibiotics. For example, S. Aureus exhibited resistance to methicillin
as early as 1962, a mere 3 years after it was first exposed to the drug.20 In the context of
evolutionary timescales, antimicrobial resistance develops blindingly fast.
The final concept that must be understood in order to contextualize policy is horizontal
gene transfer. Many organisms, such as humans and animals, can only pass genetic information
from parent to offspring, and only within the same species. This is vertical gene transfer.
Bacteria, however, have an array of methods to pass genetic information from one member of a
contemporary generation to another, and between species. This concept is paramount because it
means that antibiotic resistant traits are dangerous in all species of bacteria, not just the ones that
cause disease.21 When a patients or livestock take antibiotics, it subjects all susceptible bacteria
within them to the same selective pressure. Over time, the resultant traits spread throughout the
chain of commerce and can extend even to the farthest reaches of the world.
GLOBAL RESPONSE
Because antimicrobial resistance is a global problem, there necessarily exists
international cooperation in combatting it. Due to the phenomenon of globalization, national
action plans are not sufficient to combat the problem by themselves.22 Microbes move freely
about the world, unhindered by borders, and cross oceans in the process of global trade. The
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central coordinator of international efforts to combat antimicrobial resistance is the United
Nations (UN). Most initiatives and policies occur through the World Health Organization
(WHO), but some activity also that takes place through the Food and Agriculture Organization
(FAO), the Organization for Animal Health (OIE), the office of the Secretary General and the
General Assembly.
A. UN General Assembly
In 2015, the UN General Assembly passed Resolution 70/183, which, among other
things, called upon heads of state to hold a meeting to address the growing problem of
antimicrobial resistance.23 Included in this resolution is the globally unified recognition that
“antimicrobial resistance threatens the sustainability of the public health response to many
communicable diseases, including tuberculosis, malaria and HIV/AIDS.”24 Particularly notable
here is the mention of malaria. Although its localized eradication has eliminated it as a threat in
the United States, it is nevertheless one of the deadliest infectious diseases in the world, claiming
an annual toll of 212 million infections and 429,000 fatalities.25 The fact that the protozoan
parasite that causes the disease is developing antimicrobial resistance has a particularly
devastating impact on developing nations.26
As a result of the 2016 meeting of the heads of state called for by Resolution 70/183,
member nations passed Draft Declaration 16-16108. This draft declaration contained another
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General Assembly Resolution 70/183, Global health and foreign policy: strengthening the
management of international health crises, A/RES/70/183 (17 December 2015), available from
https://undocs.org/A/RES/70/183.
24 Id.
25 Malaria Drug Resistance, IVERMECTIN EXPOSURE IN SMALL CHILDREN STUDY GROUP |
WORLDWIDE ANTIMALARIAL RESISTANCE NETWORK(2014), http://www.wwarn.org/aboutus/malaria-drug-resistance (last visited Dec 14, 2018).
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affirmation of global consensus regarding the critical nature of the crisis of antimicrobial
resistance, this time from a gathering of many of the world’s heads of state. It also contained the
resolution of the member heads of state to each form their own national action plans for the
purpose of combatting the crisis.27 Other notable language from the declaration includes the
recognition that “achievements of the twentieth century are being gravely challenged, in
particular: the reduction in illness and death from infectious diseases achieved through social and
economic development; access to health services and to quality, safe, efficacious and affordable
medicines…”28 This language accurately captures the severity of the problem.
The totality of the actions of the UN General Assembly consistently display situational
awareness and an appropriate tone. They rightly account for the scientific consensus regarding
the gravity of the problem and demonstrate a global commitment to solving it. However, they
contain no mechanism to enforce consequences for any nation that fails to follow the resolution
and draft declaration. If a member nation were to undergo a sudden, drastic change in
governmental leadership as, for example, the United States did shortly after the passage of the
draft declaration on September 21, 2016, nothing could compel it to uphold the promises of its
former head of state. Furthermore, if a member nation were to fail to effectively combat the
problem due to persistent monetary incentives to use antimicrobial products in situations that are
not medically necessary, then the international community is similarly left without recourse.
B. Office of the UN Secretary General
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United Nations, Draft Declaratoin 16-16108, Draft political declaration of the high-level
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Another action taken by the UN to facilitate the worldwide fight against antimicrobial
resistance is the formation of the Interagency Coordination Group (IACG) by the Secretary
General. The purpose of the IACG is to effectuate communication and collaboration between the
several UN organizations that have separate interests and responsibilities in controlling the
antimicrobial resistance crisis.29 These organizations include the WHO, the FAO, and the OIE.30
Although there are no affirmative plans put forward by the IACG, it is worthy of mention
because it accounts for the interconnectivity of reserves of antimicrobial-resistant traits discussed
earlier. Only by ensuring that all sectors of the global economy that contribute to the problem are
fighting it effectively can the problem be sufficiently mitigated.
An example of cross-organizational cooperation can be found in the World Antibiotics
Awareness Week, which takes place every November. All three organizations have observance
programs which include public events across the globe and ways for individuals and
organizations to get involved.31 Lack of general public awareness is one of the most difficult
challenges that the effort to combat antimicrobial resistance faces. Much like with global climate
change before it was popularized, the low general awareness makes it difficult to galvanize
action. The fact that there is a synchronized effort to spread the word across the world is critical
to response efforts across the globe.
C. WHO
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UN Interagency Coordination Group on Antimicrobial Resistance, WORLD HEALTH
ORGANIZATION(2018), https://www.who.int/antimicrobial-resistance/interagency-coordinationgroup/en/ (last visited Dec 14, 2018).
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The WHO is one of the three UN organizations with a primary role in the response to
antimicrobial resistance. It has a main program that is a part of the effort to combat the crisis.
The WHO’s Global Action Plan (GAP) is a five-pronged strategy for how to proceed in
the global response to antimicrobial resistance. The five objectives of the plan are to: (1) improve
awareness and understanding of antimicrobial resistance through effective communication,
education, and training; (2) strengthen the knowledge and evidence base through surveillance
and research; (3) reduce the incidence of infection through effective sanitation, hygiene, and
infection prevention measures; (4) optimize the use of antimicrobial medicines in human and
animal health; and (5) develop the economic case for sustainable investment that takes account
of the needs of all countries, and increase investment in new medicines, diagnostic tools,
vaccines and other interventions.32
All of the WHO’s actions in response to antimicrobial resistance are guided by the prongs
of the GAP. World Antibiotic Awareness Week is an example of the first prong. In accordance
with the second prong, the WHO has proposed that there be a recognized international standard
for the collection of data and antimicrobial resistance in human health, and a global form for the
rapid sharing of information about the crisis, both of which currently do not exist.33 In
accordance with the third prong, the WHO has advocated for the widespread use of
immunizations and vaccinations to prevent incidence of infection.34 In accordance with the
fourth prong, the WHO has resolved that the scientific consensus supports the conclusion that the
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Global Action Plan on Antibiotic Resistance (2015), available from
http://www.wpro.who.int/entity/drug_resistance/resources/global_action_plan_eng.pdf (last
visited Dec 14, 2018).
33 Id. at 9.
34 Id.
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massive volume of antimicrobials being used worldwide is driving the problem of resistance.35 In
accordance with the fifth prong, the WHO has suggested that novel drugs and screening
technology be made available and affordable, so as to satisfy the needs of all member nations.36
The GAP concludes by setting a framework for its implementation in which it urges member
nations to develop similar plans and apply them nationally.
Overall, the GAP, like many of the other international efforts to coordinate a response to
antimicrobial resistance, shows apt cognizance of the issues and suggests reasonable and
effective measures to combat the problem. However, also like its counterpart international
efforts, it fails to recognize the immense difficulty that member nations will face in
implementing these plans despite the entrenched monetary incentives to use antimicrobial
products when not medically necessary.
D. FAO and OIE
The FAO and OIE have each promulgated similar four-pronged strategies for how their
respective domains will proceed in the global response. The FAO’s plan is to: (1) improve
awareness on AMR and related threats; (2) develop capacity for surveillance and monitoring of
AMR and AMU (antimicrobial use) in food and agriculture; (3) strengthen governance related to
AMU and AMR in food and agriculture; and (4) promote good practices in food and agricultural
systems and the prudent use of antimicrobials.37
Again, the familiar themes of awareness and monitoring, both fundamental elements that
need improvement, are mentioned first. The third prong, however, deviates from the other plans
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Id. at 10.
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in a way that is encouraging. When the plan says to, “strengthen governance,” it advocates for
member governments to compel their food and agriculture industries to use antimicrobials more
judiciously. Despite its lack of binding authority, this plan recognizes that a large obstacle in its
implementation is the ability and willingness of member governments to compel industry to
make monetary sacrifices to solve a long-term public health problem.
The OIE’s plan is identical on the first three prongs, but the fourth is to implement
international standards. This is a sensible inclusion because the existence of international
standards for the prudent use of antimicrobials will streamline the process of global advocacy to
curtail their rampant overuse.
When viewed as a whole, the coordinated international response to antimicrobial
resistance, though unequivocally moving in the right direction, is insufficient on its own to
remove the problem as a threat. Although programs like WHO’s Global Antimicrobial
Surveillance System (GLASS), a means to achieve the second prong of the GAP by establishing
an internationally accessible and comprehensive surveillance system for the detection of new
antimicrobial resistant traits,38 create real positive change, that change is not enough without
member nations curbing the overuse of antimicrobial products.
DOMESTIC RESPONSE
The United States government has its own set of plans and has taken its own set of
actions to deal with the antimicrobial resistance crisis within its borders. These include both
regulations with binding authority and industrial suggestions without any means of enforcement.
The plans and actions are promulgated both by government agencies and by industry leaders.
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(GLASS), WORLD HEALTH ORGANIZATION(2016),
http://www.who.int/drugresistance/surveillance/glass-enrolment/en/ (last visited Dec 14, 2018).
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A. CDC
The Center for Disease Control (CDC) has both implemented programs and promulgated
plans for dealing with antimicrobial resistance domestically. Much of what it does nationally is
analogous to what the WHO does internationally.
i.

Surveillance

The CDC participates in partnership with the FDA in the National Antimicrobial
Resistance Monitoring System (NARMS).39 In many ways, NARMS is the domestic equivalent
of GLASS. It monitors and records emergent antimicrobial traits and their presence in pathogens.
This, like all surveillance, is an effective tool in the fight to mitigate the effects of antimicrobial
resistance, but it cannot remove the presence of selective pressure. As long as antimicrobial
products are still overused, the problem will continue to grow.
Additionally, the CDC has promulgated a list of response tiers to prioritize the threats
posed by the many antimicrobial-resistant pathogens that are on record. The tiers are: (1)
organisms whose mechanisms of resistance are novel to the United States, or that are panresistant (e.g. Vanomycin-resistant S. Aureus [VRSA])40; (2) multi-drug resistant organisms
(MDROs) that are typically found in healthcare settings, but not generally in the surrounding
region;41 and (3) MDROs that have already been identified and established in the United States.42
ii.

Five-point plan
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National Antimicrobial Resistance Monitoring System for Enteric Bacteria
(NARMS), CENTERS FOR DISEASE CONTROL AND PREVENTION(2018),
https://www.cdc.gov/narms/about/index.html (last visited Dec 14, 2018).
40 Healthcare-associated Infections, CENTERS FOR DISEASE CONTROL AND PREVENTION(2018),
https://www.cdc.gov/hai/containment/guidelines.html (last visited Dec 14, 2018).
41 Id.
42 Id.
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The CDC, in compliance with the WHO’s GAP, has promulgated its own five-point plan
to combat antimicrobial resistance. The prongs are: (1) awareness and education; (2)
surveillance; (3) infection prevention and control; (4) optimization of use; and (5) R&D and
investment.
These tiers and plans are effective to facilitate the containment of already-existing
MDROs, but like the surveillance programs, do not effectively deal with the problem of selective
pressure, and are not enough on their own. Point 4, optimization of use, would account for the
necessity for judicious use of antimicrobial products, but without a means to compel industry to
comply, it is ineffective.
The CDC has the power to promulgate regulations, but it is not the ideal government
agency to pass regulations banning the overuse of antimicrobial products. Although it has the
power the power to enact regulations to control the spread of infectious diseases,43 this power is,
with one exception, limited to the function of quarantine powers in times of emergency and war.
That exception is that the Surgeon General may, with the approval of the secretary, make and
enforce regulations that are, “necessary to prevent the introduction, transmission, or spread of
communicable diseases from foreign countries into the States or possessions, or from one State
or possession into any other State or possession.”44
resistance, which is rather the development of resistant traits in already extant diseases.
B. FDA

43
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See 42 U.S.C. §264.
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The Food and Drug Administration (FDA) unquestionably has the authority to regulate,
ban, or otherwise limit the use of antimicrobial chemicals because they are drugs. In their hands
is the power to compel industry to act.
i.

Antibacterial Soap

One decisive action that the FDA has taken to secure the judicious use of antimicrobial
products and combat antimicrobial resistance was ban the sale soaps that use certain antibacterial
compounds, most prominently triclosan.45 These products, advertised as killing bacteria, are not
more effective at cleaning than non-bactericidal soaps. This is because soap cleans by
emulsifying the germs on surfaces and making them water soluble, allowing water to physically
remove them from a surface. The needless addition of a bactericidal effect does nothing salutary,
and in fact applies selective pressure to bacteria that are exposed to it, contributing to
antimicrobial resistance.
However, the final rule that banned these antibacterial soaps is imperfect. It only banned
a limited list of antibacterial chemicals, not bactericidal effects in general.46 Thus, antibacterial
soaps using chemicals that are not on the list may still be sold, and industrial chemists are free to
develop more chemicals for use in soaps that would kill bacteria. In this way, antibacterial soap
maintains a limited presence in the market, and the label “kills 99.9% of germs and bacteria”
may still appeal to the general consumer.
ii.

Agricultural Industry

Antibiotic use in the agricultural industry, comprising over 80% of the world’s antibiotic
use, is different from ordinary medical use. Antibiotics are used in limited capacity on livestock

45
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81 FR 61106
Id.
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to preemptively prevent or reactively treat diseases, but their main use is that when they are
added to livestock’s feed, they improve the feed conversion ratio of the livestock.47 The feed
conversion ratio is the ratio to the cost to feed an animal to the revenue yielded by selling its
products. In other words, antibiotics make livestock grow larger for less money. In fact, they
increase the feed conversion ratio between 3% and 9%, and the total size of livestock between
2% and 10%.48 Considering the amount of meat that is produced in the United States annually,
antibiotics account for a significant profit.
To combat the crisis of antibiotic resistance, the FDA has promulgated Guidelines for
Industry (GFI), to communicate the best practices and the agency’s current thinking on topics of
interest. The two GFIs that address antibiotic use in agriculture are GFI #20949 and GFI #213.50
GFI #209 addresses the problem that superfluous use of antibiotics in animal feed is
wildly exacerbating the problem of antimicrobial resistance. This occurs because of horizontal
gene transfer; the danger does not particularly lie in the pathogenic bacteria that get refined by
the rampant use of antibiotics, but the development of resistance traits in non-pathogenic bacteria
that are then transferred to pathogenic bacteria as the meat from the livestock travels down the
stream of commerce. This GFI articulates a progressive and solution-oriented position by the
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FDA, stating, “[the] FDA is providing a framework for the voluntary adoption of practices to
ensure the appropriate or judicious use of medically important antimicrobial drugs in foodproducing animals.”51 Furthermore, to achieve this end, the FDA prescribes two main modes of
action, which are: “(1) limiting medically important antimicrobial drugs to uses in foodproducing animals that are considered necessary for assuring animal health; and (2) limiting such
drugs to uses in food-producing animals that include veterinary oversight or consultation.”52
Although the distinction of “medically important” drugs, defined in a footnote as drugs
“important for therapeutic use in humans,”53 allows compliant companies to curtail their use of
antibiotics while ignoring the underlying problem posed by horizontal gene transfer, any
decrease in the use of antibiotics in farming is a massive victory toward impeding antimicrobial
resistance.
GFI #213 expands on some of the restrictions set forth in GFI #209 while loosening. It
states that its purpose is to help phase out the use of “medically important” drugs in livestock for
non-medical purposes entirely.54 It expands a level of oversight for certain drugs whereby
compliant companies would need to obtain a Veterinary Feed Directive (VFD) in order to infuse
animal feed with antibiotics, certifying that it is medically necessary.55 A VFD is less stringent of
a barrier to obtaining antibiotics than a prescription is.56 It moves many drugs that were once
prescription-only into the category of VFD, thus expanding access to those drugs. However, it
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Supra note 44 at 3.
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54 Supra note 45 at 4.
55 Id.
56 Id.
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also moves many drugs that were once available over the counter to VFD, thus limiting access to
those drugs.57
Overall, the liberality with which a veterinarian may issue a VFD is concerning,
especially considering the tendency of companies form working relationships with veterinarians.
Additionally, the retention of the label “medically important” to the drugs being phased out
leaves the same problems that were present in GFI #209 unresolved.
Accompanying the continued permissiveness of antibiotic use in compliant companies,
the GFI’s have one additional fatal flaw. In both GFI #209 and GFI #213, there is a block of text
just before the introduction that states that the entire document is nonbinding.58
This means that compliance with FDA GFI’s is entirely voluntary. Should a company
wish to simply use antibiotics at its own will to maximize profits, it is free to do so. Thus, using
antibiotics in animal feed is still a common practice to this day. Some industry leaders, such as
Tyson, offer antibiotic-free options for beef and pork at a markup alongside their antibiotic-fed
options.59 Although the argument can be made that allowing consumers to vote with their wallets
leaves an avenue to affect change at the supermarket, most people just want an affordable cut of
meat, which limits the effect that a conscientious bloc of consumers can have. Rather, the
antibiotic-free label is a token offering, an excuse to charge some conscientious consumers or
misguided health-conscious consumers a markup, standing brazenly in defiance of the global
imperative to halt the superfluous use of antimicrobial drugs.
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C. Medical Industry
The remainder of global antimicrobial use is for medical purposes. Unfortunately, the
over-prescription of antibiotics is a rampant problem, especially in the developed world. There
are many causes for this worldwide overuse, ranging from misperceptions about the role of
physicians to perverse incentive structures for the physicians themselves.
In the United States, approximately 1 in every 3 prescriptions for a course of antibiotics is
unnecessary.60 The total amount of inappropriate use of antibiotics, including inappropriate
selection, dosing, and duration, approaches 1 in every 2 uses.61
Figure 262

60

See supra note 3.
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The volume of outpatient prescriptions in an area can affect local resistance patterns.63
Figure 2 demonstrates that there is a high variance of prescription volume among the states.
However, every state still grievously over-prescribes.64
Furthermore, the bulk of the over-prescription problem occurs in outpatient settings. Over
60% of all antibiotic prescriptions in the United States occur in outpatient facilities.65 Between
80% and 90% of the total volume of antibiotics consumed by humans in the United states occur
as a result of prescriptions in an outpatient setting.66
Respiratory infections are the most common causes of antibiotic prescriptions.67
However, the majority of respiratory infections are not caused by bacteria.68 This disparity is a
microcosm of the larger problem of antibiotic over-prescription.
Among physicians, there have been numerous initiatives to promote antibiotic
stewardship. For example, the American Medical Association (AMA) has spearheaded several
plans to reduce antibiotic prescription rates. For example, in several clinics, AMA doctors
displayed an open letter, written in large font and in eighth grade-level English, about the
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importance of antibiotic stewardship. Clinics that displayed this letter saw average drops of
around 9% in antibiotic prescription rates for respiratory infections.69
The AMA is also experimenting with more overt methods to reduce prescription rates. At
some clinics, physicians that enter a diagnosis of a respiratory infection into a patient’s electronic
health record (EHR), accompanied by a prescription for antibiotics, must fill in an additional line
of text stating the justification for the prescription. If no justification is entered, the EHR displays
“NO JUSTIFICATION FOR PRESCRIBING ANTIBIOTIC.”70 Additionally physicians at
clinics are ranked by their antibiotic prescription rates, giving a sense of peer accountability. 71
Clinics that implement these experimental methods have seen a drop of 16%-18% in prescription
rates.72 These simple methods of holding physicians to some rudimentary form of accountability
make tangible progress in curbing antibiotic prescription rates. However, none of them have yet
seen widespread adaptation.73
Furthermore, the CDC makes efforts to communicate with physicians about the
importance of antibiotic stewardship. For example, it has promulgated a table of
recommendations about how to determine whether it is appropriate to prescribe antibiotics with
certain common conditions, as well listing the proper course of treatment in situations when
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antibiotics are not appropriate.74 Additionally, it offers a course on antibiotic stewardship for
continuing education credits.75
Although these efforts to stop the over-prescription problem in the United States are
admirable, they are insufficient. What is missing from the larger picture of reducing prescription
rates is any binding provision. As it stands, there is no enforced negative consequence for
physicians who unnecessarily prescribe antibiotics for illnesses that do not in fact require them.
Rather, there are perverse incentives for physicians to continue to prescribe antibiotics at
current rates. First, physicians are pressured by patients who have expectations about how their
treatment will go.76 Specifically, patients who present with an illness expect to be given a
medication that fixes their illness.77 However, there are many illnesses with no simple
pharmaceutical cures. Thus, physicians often motivated by the demand to meet consumer
expectations when they prescribe antibiotics when medically unnecessary, and when the correct
treatment is to wait for the illness to expire while treating ancillary symptoms.78
Additionally, in outpatient settings, physicians often have a limited time to meet with
patients. Often, that time is not enough to diagnose an illness and formulate a treatment plan.
Thus, physicians can rely upon prescribing antibiotics as a heuristic method of dealing with
problems.79 This problem is confounded even more by the fact that viral and bacterial infections
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often present similar symptoms. In these cases, prescribing antibiotics is preferable to the risk
physicians incur by not prescribing them.80 Often, it is more time-efficient for physicians just to
prescribe antibiotics rather than to lengthily explain why antibiotics are not required.81 These
efficiencies add up to significant amounts over time. Finally, pharmaceutical companies are
permitted to advertise to physicians through representatives. The interactions between the
representatives and the physicians, often involving gifts, influences physicians’ prescribing
habits.82
D. Research Efforts
There have been significant efforts to combat the problem of antimicrobial resistance
through researching innovative solutions. One method that researchers use to combat the
problem is to develop new antimicrobials that are not yet resisted.83 These can be effective
means of slowing the problem. However, creating new antimicrobial drugs cannot stop the
process of selective pressure, or remove the bacterial trait of horizontal gene transfer.84 New
drugs cannot be a permanent solution to antimicrobial resistance, but they can slow it
significantly.85
Phage therapy is a second avenue of research that, though underdeveloped relative to
antimicrobials, may provide promising results in the future.86 It functions by combatting bacterial
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infections using bacteriophages, or viruses that infect bacteria.87 These phages are harmless to
humans and highly specific infectors of their bacterial targets.88 Through controlled introduction
to an infected patient, phage therapy may one day be able to defeat bacterial infection as
effectively as antibiotics would.89 The bacteria would not stop evolving, and would develop
resistances to bacteriophage infection the same way they develop resistances to antibiotics.90
However, there is evidence that suggests that when bacteria develop resistance to bacteriophages,
they sacrifice resistances to antibiotics, and when they develop resistances to antibiotics, they
sacrifice resistances to bacteriophages.91 Thus, phage therapy, once developed, remains a
promising hope to bringing a permanent end to the threat of antimicrobial resistance in the
future.
CONCLUSION
Antimicrobial resistance is a long-term danger with potentially disastrous results. If
current levels of antimicrobial product use do not drop, the phenomenon threatens to undo some
of the landmark achievements of human development, such as the lowered deaths from
infectious diseases and the reduction in infant and child mortality.
Global efforts to impede its progression focus primarily on surveillance, monitoring, the
development of new drugs, and the spreading of awareness. These are effective tools, and the
world is objectively better off as a result of these efforts. However, they paint an incomplete
picture of the solution to antimicrobial resistance.
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Selective pressure is a natural law that acts constantly on every organism alive. It,
compounded with the bacterial phenomenon of horizontal gene transfer, indicate that there can
be no sufficient solution to antimicrobial resistance without limiting the use of antimicrobial
products to situations where they are medically necessary.
The rampant over-prescription of antimicrobial drugs, combined with the commonplace
use of antibiotics in animal feed, accelerate the problem of antimicrobial resistance more than the
current combined totality domestic and global efforts are able to slow it down. Therefore, the
response to the problem is insufficient. Only by compelling physicians and agricultural
companies to cease the superfluous use of antimicrobial products can a response to the crisis be
effective enough to mitigate the damage caused by the rapid global development of antimicrobial
resistance.
However, there remains hope that through continued research, humanity may develop a
permanent solution to the problem. The continued development of new drugs, and promising
research into the relatively novel field of phage therapy, shine as beacons of hope that in the long
term, antimicrobial resistance is solvable.

27

